Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy

被引：0
|
作者：
Sorrentino, J. A. [1 ]
Lai, A. [1 ]
Weiss, J. M. [2 ]
Dragnev, K. H. [3 ]
Owonikoko, T. K. [4 ]
Adler, S. [5 ]
Antal, J. M. [5 ]
Malik, R. K. [5 ]
Roberts, P. J. [1 ]
机构：
[1] G1 Therapeut Inc, Translat Med, Res Triangle Pk, NC USA
[2] Univ N Carolina, Hematol Oncol, Chapel Hill, NC 27515 USA
[3] Dartmouth Hitchcock Med Ctr, Hematol Oncol, Norris Cotton Canc Ctr, Lebanon, PA USA
[4] Emory Univ, Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[5] G1 Therapeut Inc, Clin Dev, Res Triangle Pk, NC USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1671P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
    Zhou, Fei
    Zhao, Wencheng
    Gong, Xiaomei
    Ren, Shengxiang
    Su, Chunxia
    Jiang, Tao
    Zhou, Caicun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [32] COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
    Bilir, S. P.
    Ogale, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S36
  • [33] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [34] SERUM ALBUMIN PREDICTS OUTCOME IN PATIENTS WITH EXTENSIVE STAGE SMALL-CELL LUNG CANCER (ES-SCLC) RECEIVING FIRST-LINE COMBINATION OF PD(L)1 INHIBITORS AND PLATINUM-ETOPOSIDE CHEMOTHERAPY
    Lamberti, Giuseppe
    Ricciuti, Biagio
    Vaz, Victor
    Alessi, Joao Victor
    Pecci, Federica
    Di Federico, Alessandro
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A471 - A471
  • [35] French real world study on patient characteristics and treatment strategies in first-line of extensive-stage small cell lung cancer (ES SCLC)
    Debieuvre, D.
    Dayen, C.
    Dixmier, A.
    Gally, S.
    Pau, D.
    Greenwood, W.
    Falchero, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1038 - S1038
  • [36] Prognostic impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ishihara, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S684 - S685
  • [37] Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy
    Abraham, Ivo
    Onyekwere, Uchenna
    Deniz, Baris
    Moran, Donald
    Chioda, Marc
    MacDonald, Karen
    Huang, Huan
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 : 71 - 83
  • [38] Identifying Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit From Intensive Radiation Therapy
    Slotman, B. J.
    Faivre-Finn, C.
    van Tinteren, H.
    Keijser, A.
    Praag, J. O.
    Knegjens, J.
    Hatton, M.
    van Dam, I.
    van der Leest, A.
    Reymen, B.
    Stigt, J.
    Haslett, K.
    Tripathi, D.
    Smit, E.
    Senan, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S153 - S154
  • [39] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
    Shi, Jian
    Liu, Jiayin
    Duan, Xiaoyang
    Huang, Guanglei
    Wang, Lixing
    Zhao, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
12345